![Sample our Social Sciences journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110822/TOC-Subject-Sample-2021-Social-Sciences.jpg"})
Abstract
Stephen B Baylin is a codirector of the Cancer Biology Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Virginia and DK Ludwig Professor of Oncology and Medicine. Baylin attended Duke University, where he earned his medical degree and completed his internship and first year residency in internal medicine. He then worked for 2 years at the National Heart and Lung Institute of the NIH. In 1971, he joined the departments of oncology and medicine at Johns Hopkins University School of Medicine. His research interests include cellular biology and genetics of cancer, specifically epigenetics or genetic modifications other than those in DNA that can affect cell behavior, and silencing of tumor suppressor genes and tumor progression. His research has looked at the mechanisms through which variations in tumor cells derive, and cell differentiation in cancers such as medullary thyroid carcinoma and small-cell lung carcinoma. He has served on the American Association for Cancer Research Board of Directors, and is an associate editor of Cancer Research. He has also presented frequently at AACR conferences and chaired the special conference on ‘DNA Methylation, Imprinting and the Epigenetics of Cancer’. He has authored or coauthored more than 370 publications.
Disclaimer
The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of Future Medicine Ltd.
Financial & competing interests disclosure
SB Baylin consults for MDx Health in agreement with the Johns Hopkins School of Medicine. MDx Health licences, from the School of Medicine, the technology of methylation specific PCR for detection of DNA methylation abnormalities and is entitled, as well as the author, to royalties from sales involved with this technology. SB Baylin has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.